PARIS (Reuters) - Healthcare and clinical diagnostics company Novacyt announced more contract wins for its 'Primerdesign' product aimed at testing for the presence of the coronavirus, although the company suffered a minor setback in France.
Novacyt said it had total sales and confirmed orders worth 135 million euros ($150.3 million) for the product, with new wins in Zimbabwe and across Latin America.
